Extended Data Table 4 Characteristics and management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in patients who received the two step-up priming regimen

From: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

  1. CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; TEAE, treatment-emergent adverse event.
  2. *The 4 patients who did not receive the two step-up priming regimen were excluded from this CRS and ICANS analysis.
  3. sIncludes tocilizumab and siltuximab.
Back to article page